THYROID CANCERS

During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.

Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from other clinical trials.

Noah S. Kalman, MD, MBA, discusses how oncologists can determine the best course of action for the treatment and management of a patient with thyroid cancer.

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in differentiated thyroid cancer in the first article of a 2-part series.

Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients with anaplastic thyroid cancer.

Noah S. Kalman, MD, MBA, highlighted advancements in thyroid cancer treatment, emphasizing personalized therapies, molecular testing, and optimizing traditional approaches.

Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognoses.

The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary thyroid cancer in patients aged 2 years and older.

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of.

Francis P. Worden, MD, discusses a real-world study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer.

The study found that lenvatinib continued to demonstrate improved efficacy in patients with radioiodine-refractory differentiated thyroid cancer.

Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and thymic carcinoma.

Francis P. Worden, MD, discusses the background of a study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer, including in those with BRAF-mutated, wild-type and BRAF untested tumors.

Selpercatinib led to high response and progression-free survival rates among patients who were treatment naive and pretreated with RET-altered thyroid cancers.

AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.

Francis P. Worden, MD, discusses future plans to investigate combination therapies and other novel treatments in the thyroid cancer space.

In an interview with Targeted Oncology, Francis P. Worden, MD, delved into the rationale behind the study and the implications of this research for patients with radioidine-refractory differentiated thyroid cancer.

During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.

Francis P. Worden, MD, provides a brief overview of the approval of selpercatinib and what it means for patients with RET fusion-positive thyroid cancer.

Cesar Augusto Perez, MD, discusses one of the top unmet needs that exists in the thyroid cancer space.

The approval of selpercatinib marks the first targeted therapy for pediatric patients with RET gene alterations in solid and thyroid tumors.